News (138)

FDA Sets June 10 Advisory Panel Meeting on Eli Lilly Alzheimer's Drug DJ
Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego PR
Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego PR
Lilly to Participate in Evercore ISI HealthCONx Conference PR
Eli Lilly and Company Announces Executive Changes CI
Eli Lilly Diabetes, Obesity Head Mike Mason to Retire DJ
Lilly Announces Leadership Transitions PR
Lilly to Participate in Morgan Stanley 21st Annual Global Healthcare Conference PR
Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease PR
ELI LILLY & CO : Change in Directors or Principal Officers (form 8-K) AQ
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss PR
Lilly to Participate in Citi's 17th Annual BioPharma Conference PR
Lilly to Participate in Bank of America Securities 2022 Healthcare Conference PR
Eli Lilly obesity drug data shines, shares rise RE
Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19 PR
Eli Lilly pushes back timeline for Alzheimer's drug application RE
Eli Lilly and : Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting - Form 8-K PU
Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting PR
Lilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference PR
Eli Lilly Gets Expanded FDA EUA for Covid-19 Treatment for Some High-Risk Individuals DJ
Regeneron Pharmaceuticals : U.S. buys additional doses of Eli Lilly, Regeneron COVID-19 therapy RE
Eli Lilly bets on Alzheimer's disease drug data as it chases Biogen RE
Eli Lilly and : Lilly to Participate in Guggenheim Biopharma Strategy Series PR
MYRIAD GENETICS INC : Submission of Matters to a Vote of Security Holders (form 8-K) AQ
Transcript : Myriad Genetics, Inc. - Shareholder/Analyst Call
Eli Lilly and : Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S. AQ
Lilly Ends U.S. Use of Single Covid-19 Antibody Drug Alone -- Update DJ
New Covid-19 Strains Prompt Lilly to Seek to End U.S. Use of Single Antibody Drug Alone DJ
Eli Lilly and : Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19 AQ
Myriad Genetics : Annual Transition Report (SEC Filing - 10-KT) PU
Lilly Alzheimer's drug shows benefit on cognition, function in mid-stage trial RE
Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM PR
Eli Lilly's combo therapy for COVID-19 cuts serious illness and death in large study RE
Eli Lilly and Company : - Lilly to Participate in Cowen Health Care Conference AQ
Eli Lilly and : Lilly to Participate in Cowen Health Care Conference PR
Eli Lilly and : Lilly's bamlanivimab administered with etesevimab receives FDA emergency use authorization for COVID-19 AQ
Eli Lilly and : Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab with VIR-7831 for COVID-19 AQ
Eli Lilly and Company : - New data show treatment with Lilly's neutralizing antibodies bamlanivimab and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent AQ
GlaxoSmithKline : Eli Lilly, Vir Partner on Therapy for Moderate Covid-19 Cases DJ
Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19 GL
Eli Lilly and Company : - Lilly's neutralizing antibody bamlanivimab prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents AQ
Eli Lilly and : Lilly Antibody Drug Prevents Covid-19 in Nursing Homes, Study Finds DJ
Eli Lilly and : Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents PR
Eli Lilly and Company : - Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial AQ
Regeneron Pharmaceuticals : says antibodies likely potent vs virus variants, Lilly concerned about S. Africa version RE
1234NextSee all

Companies (19)

BROWN-FORMAN CORPORATION 23 045 M $
Logo Brown-Forman Corporation

Brown-Forman Corporation is among the main American producers of spirits and wines. The activity is organized around two families of products: - spirits : whiskies (Jack Daniel's, Canadian Mist, Early Times Kentucky brands), vodkas (Finlandia), tequilas ...

BROWN-FORMAN CORPORATION 23 045 M $
Logo Brown-Forman Corporation

Brown-Forman Corporation is among the main American producers of spirits and wines. The activity is organized around two families of products: - spirits : whiskies (Jack Daniel's, Canadian Mist, Early Times Kentucky brands), vodkas (Finlandia), tequilas ...

BROWN-FORMAN CORPORATION 23 045 M $
Logo Brown-Forman Corporation

Brown-Forman Corporation is among the main American producers of spirits and wines. The activity is organized around two families of products: - spirits : whiskies (Jack Daniel's, Canadian Mist, Early Times Kentucky brands), vodkas (Finlandia), tequilas ...

ARCHER-DANIELS-MIDLAND COMPANY 30 467 M $
Logo Archer-Daniels-Midland Company

Archer-Daniels-Midland Company is one of the world's leading transformers of agricultural products into food ingredients, fuels, and industrial products. Net sales break down by activity as follows: - agricultural services (78.3%): manufacturing and sale ...

ARCHER-DANIELS-MIDLAND COMPANY 30 467 M $
Logo Archer-Daniels-Midland Company

Archer-Daniels-Midland Company is one of the world's leading transformers of agricultural products into food ingredients, fuels, and industrial products. Net sales break down by activity as follows: - agricultural services (78.3%): manufacturing and sale ...

DILLARD'S, INC. 7 086 M $
Logo Dillard's, Inc.

Dillard's, Inc. is a retailer of fashion apparel, cosmetics and home furnishings. The Company operates through two segments: the operation of retail department stores and a general contracting construction company. It operates over 273 Dillard’s stores, ...

ISRAMCO NEGEV 2 LIMITED PARTNERSHIP 1 124 M $
Logo Isramco Negev 2 Limited Partnership

Isramco Negev 2 LP is engaged in the exploration and extraction of oil and natural gas based in Israel. The Company works in cooperation with Isramco Oil and Gas Ltd. and Isramco Management (1988) Ltd. The Company's interests include Med Yavne (49.8633%), ...

TINTRA PLC 11 M $
Logo Tintra PLC

Tintra Ltd is a United Kingdom-based financial technology (fintech) company. The Company is focused on artificial intelligence that optimizes payment processes and compliance especially between emerging and developed markets. Using end-to-end artificial i ...

OPHIR GOLD CORP. 8 M $
Logo Ophir Gold Corp.

Ophir Gold Corp. is a Canada-based diversified exploration company. The Company’s principal business activities include the acquisition and exploration of mineral property assets. The Company’s Breccia property consists of 102 mining claims covering a ...

TRUWORTHS LIMITED - $
Logo Truworths Limited

Truworths Limited specializes in the design, manufacturing and marketing of clothes and accessories for men and women. Net sales break down by activity as follows: - retail distribution of clothes and accessories (98.6%): Nine West, Guess, Ka'yanda, Bert ...


12Next

Insiders

Picture Daniel Skovronsky
Daniel Skovronsky

Daniel M. Skovronsky founded Avid Radiopharmaceuticals, Inc. Dr. Skovronsky is on the board of Myriad Genetics, Inc. and The Indianapolis Museum of Art, Inc. and Chief Scientific Officer & Senior Vice President at Eli Lilly & Co. and Member of the University of Pennsylvania. Daniel M. Skovronsky previously was Chief Executive Officer at Avid Radiopharmaceuticals, Inc. Dr. Skovronsky received a doctorate from the University of Pennsylvania, an undergraduate degree from Yale University and a doctorate from Perelman School of Medicine.



Picture Daniel Daniel
Daniel Daniel

Daniel D.
Daniel
is the founder of Twenty Acre Capital LP.
He is currently the Lead Independent Director at Domo, Inc. since 2020.
Previously, he worked as a Director at BlackRock Advisors LLC from 2011 to 2019.
Before that, he was a Special Situations Analyst at UBS Securities LLC in 2010 and at Wall Street Access LLC in the same year.
Mr. Daniel completed his undergraduate degree at the University of Utah in 1999 and earned an MBA from The Wharton School of the University of Pennsylvania in 2002.






Picture Daniel
Daniel

Daniel - was the founder of Digital Venue and held the title of Chairman.


Picture Daniel
Daniel

Currently, Mr. Daniel is President Director at PT Organon Pharma Indonesia Tbk.


No results for this search